



RPG LIFE SCIENCES LIMITED
Unit No. 208-213, B Wing,
Bezzola Complex,
Sion-Trombay Road, Chembur,
Mumbai 400071, India
Tel: +91-22-25292152-55
Fax: +91-22-25297423

January 25, 2022

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C1, 'G' Block, Bandra-Kurla Complex
Bandra (East), Mumbai 400 051.

BSE Limited
Corporate Relationship Department Floor
25, P.J. Towers
Dalal Street
Mumbai 400 001.

Symbol: RPGLIFE

Scrip code: 532983

Dear Sirs,

Sub: Unaudited Financial Results for the quarter and nine months ended December 31, 2021

Pursuant to Regulation 33 Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Unaudited Financial Results for the quarter and nine months ended December 31, 2021 which were approved by the Board of Directors of the Company, at its meeting held on January 25, 2022 along with Limited Review Report issued by the Statutory Auditors of the Company.

The meeting commenced at 03:00 p.m. and concluded at 05:15 p.m.

Kindly take the above on record.

Thanking you,

Yours faithfully,
For RPG Life Sciences Limited

Rajesh Shirambekar
Head – Legal & Company Secretary



Encl.: as above.

B S R & Co. LLP

Chartered Accountants

14th Floor, Central B Wing and North C Wing,
Nesco IT Park 4, Nesco Center,
Western Express Highway, Goregaon (East),
Mumbai - 400 063, India

Telephone: +91 22 6257 1000
Fax: +91 22 6257 1010

Limited Review Report on unaudited financial results of RPG Life Sciences Limited for the quarter ended 31 December 2021 and year-to-date results for the period from 01 April 2021 to 31 December 2021 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of RPG Life Sciences Limited

1. We have reviewed the accompanying Statement of unaudited financial results of RPG Life Sciences Limited ("the Company") for the quarter ended 31 December 2021 and year-to-date results for the period from 01 April 2021 to 31 December 2021 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **B S R & Co. LLP**
Chartered Accountants

Firm's Registration No.:101248W/W-100022

REKHA SHENOY
Digitally signed by
REKHA SHENOY
Date: 2022.01.25
15:43:44 +05'30'

Rekha Shenoy
Partner

Membership No.: 124219
UDIN:22124219AAAAAB8077

Mumbai
25 January 2022

Registered Office:

(Rs. in Lakhs)

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2021

Particulars	Quarter ended			Nine months ended		Year ended
	31-12-2021	30-09-2021	31-12-2020	31-12-2021	31-12-2020	31-03-2021
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 Revenue from Operations	11,558	11,265	10,760	33,636	29,638	38,914
2 Other Income	61	71	12	173	61	91
3 Total Income (1+2)	11,619	11,336	10,772	33,809	29,699	39,005
4 Expenses						
(a) Cost of Materials Consumed	2,526	1,899	2,175	6,512	6,769	8,575
(b) Purchases of Stock-in-Trade	2,530	2,217	1,517	6,231	3,831	5,036
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(1,433)	(673)	131	(2,182)	(753)	(501)
(d) Employee Benefits Expense	2,556	2,577	2,437	7,493	7,186	9,466
(e) Finance Costs	16	17	16	46	70	79
(f) Depreciation and Amortisation Expense	393	399	419	1,188	1,255	1,647
(g) Other Expenses	2,969	2,665	2,370	8,297	6,878	9,345
Total Expenses	9,557	9,101	9,065	27,585	25,236	33,647
5 Profit before tax (3-4)	2,062	2,235	1,707	6,224	4,463	5,358
6 Income tax expenses						
a. Current Tax	618	670	536	1,866	1,420	1,715
b. Deferred Tax	(19)	(10)	(116)	(38)	(265)	(357)
7 Profit for the period (5-6)	1,463	1,575	1,287	4,396	3,308	4,000
8 Other Comprehensive Income						
(i) Items that will not be reclassified to Profit or Loss	(4)	(4)	(6)	(12)	(18)	(16)
(ii) Income tax relating to items that will not be reclassified to Profit or Loss	1	1	2	3	5	4
Other Comprehensive Income Net of Tax	(3)	(3)	(4)	(9)	(13)	(12)
9 Total Comprehensive Income for the period (7+8)	1,460	1,572	1,283	4,387	3,295	3,988
10 Paid-up Equity Share Capital (Face Value Rs.8/- each)	1,323	1,323	1,323	1,323	1,323	1,323
11 Other Equity						20,322
12 Earnings per Share (of Rs.8/- each) (not annualised for the quarter):						
(a) Basic (in Rs.)	8.85	9.52	7.78	26.58	20.00	24.19
(b) Diluted (in Rs.)	8.85	9.52	7.78	26.58	20.00	24.19

Notes:

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on January 25, 2022.
- The Company operates in only one reportable business segment i.e., Pharmaceuticals.



For RPG Life Sciences Limited


 Yugal Sikri
 Managing Director
 Mumbai, January 25, 2022